Trial record 1 of 10 for:
rheacell
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05838092 |
|
Recruitment Status :
Recruiting
First Posted : May 1, 2023
Last Update Posted : October 30, 2023
|
Sponsor:
RHEACELL GmbH & Co. KG
Information provided by (Responsible Party):
RHEACELL GmbH & Co. KG
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | December 1, 2024 |
| Estimated Study Completion Date : | December 1, 2025 |